Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Clínica Baviera, S.A. is a Spain-based medical company specializing in ophthalmology, operating a network of clinics across Spain, Germany, Austria, and Italy. It provides comprehensive diagnosis, treatment, and monitoring for a wide range of visual disorders, including myopia, hyperopia, astigmatism, presbyopia, cataracts, glaucoma, retinal conditions, strabismus, cornea issues, neuro-ophthalmology, tear ducts, oculoplasty, and advanced procedures like LASIK, LASEK, and intraocular lens implants. Additionally, it offers pediatric ophthalmology and plastic surgery services. Founded in 1992 and headquartered in Madrid, the company rebranded from Clínica Oftalmológica Baviera, S.L. to its current name in 2000. As the parent of the Baviera Group, it oversees subsidiaries such as Clinica Baviera Italia Srl and Care Vision Germany GmbH. Acquired by China's Aier Eye Hospital Group in 2017, which holds a 73.23% stake, Clínica Baviera, S.A. employs 1,847 people and plays a key role in the European healthcare facilities and services sector, focusing on specialized eye care.
€56.20
+€0.60 (+1.08%)
EOD Jun 23, 2026 · Twelve Data
Margins and capital returns are both well above average: 20.09% operating margin, ROIC at 25.23%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue grew 14.9%, still solid.
Even for strong businesses, today's 20x P/E means the stock needs to keep delivering. There's no margin of safety if growth disappoints.
20.1x earnings, 19.8x FCF. Valuation is in a reasonable range. The main question is whether the business can re-accelerate or if current trajectory is already priced in.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€309M
▲ +14.9% YoY
Net Income (TTM)
€45M
▲ +4.4% YoY
Op. Margin
20.09%
▼ -1.1pp YoY
ROIC
25.23%
▼ -1.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€45M
▲ +30.1% YoY
Op. Cash Flow (TTM)
€68M
▲ +7.6% YoY
Net Debt
€20M
Cash & Equiv.
€50M
3Y CAGR: +15.0%
3Y CAGR: +6.0%
Continue Research